Contrasting PerkinElmer (PKI) and The Competition
PerkinElmer (NYSE: PKI) is one of 80 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare PerkinElmer to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.
Institutional and Insider Ownership
91.5% of PerkinElmer shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 2.2% of PerkinElmer shares are owned by company insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares PerkinElmer and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|PerkinElmer||$2.12 billion||$234.29 million||19.89|
|PerkinElmer Competitors||$2.13 billion||$229.91 million||-32.30|
PerkinElmer’s competitors have higher revenue, but lower earnings than PerkinElmer. PerkinElmer is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. PerkinElmer pays out 7.8% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 26.1% of their earnings in the form of a dividend.
Volatility and Risk
PerkinElmer has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, PerkinElmer’s competitors have a beta of 1.27, meaning that their average stock price is 27% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for PerkinElmer and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PerkinElmer presently has a consensus price target of $68.23, suggesting a potential downside of 4.72%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.15%. Given PerkinElmer’s higher possible upside, equities research analysts clearly believe PerkinElmer is more favorable than its competitors.
This table compares PerkinElmer and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
PerkinElmer beats its competitors on 8 of the 15 factors compared.
PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.